TELO GENOMICS

Telo Genomics was created to commercialize Dr. Mai's platform technology. Its lead application is a prognostic tool, for unmet market needs, designed to address multiple stages of multiple myeloma. It is a Canadian incorporated company that trades on the Toronto Venture Stock Exchange (TSX.V: TELO) and with a head office and laboratory at the MaRS Research Centre in Toronto... Our proprietary technology TeloView®, quantifies genomic instability by measuring the 3D structure and the spatial organization of telomeres. It is designed to provide important actionable information regarding the aggressiveness of disease and potential response to treatment... Our highly predictive and non-invasive prognostic/diagnostic applications have the potential to fundamentally improve the treatment of disease

Primary location: Toronto Canada